Leica Biosystems, Indica Labs, and Lunit have entered into a strategic partnership to develop AI-powered image analysis algorithms for PD-L1 and emerging immunohistochemistry (IHC) biomarkers. This partnership aims to enable scalable and consistent biomarker quantification through computational pathology tools to enhance cancer research workflows around the world.
Expanding market-defining computational pathology ecosystem
Building on the market-defining computational pathology partnership between Leica Biosystems and Indica Labs, this new collaboration integrates Lunit’s advanced AI capabilities into a best-in-class IHC staining and digital pathology ecosystem. The first product from this three-way collaboration is the AI-powered Lunit SCOPE algorithm designed specifically for Leica Biosystems’ PD-L1 primary antibody (CAL10).
Address variability in biomarker scoring using AI
Leica Biosystems, Indica Labs, and Lunit are working together to support pharmaceutical partners in integrating AI-powered digital pathology into routine clinical research. Biomarker scores for PD-L1 and other IHC biomarkers remain highly variable because disease assessment and treatment decisions often rely on manual assessment of stained tissue under the microscope. This manual process can be time-consuming and subject to human variation.
Combining Leica Biosystems’ expertise in IHC staining and digital pathology, Indica Labs’ image management platform, and Lunit’s advanced AI analysis, this collaboration is designed to support a consistent scoring approach, enable robust biomarker analysis, and accelerate workflows in oncology research.
Seamless digital pathology workflow powered by AI
The partnership integrates Leica Biosystems’ PD-L1 IHC assay platform¹, Aperio GT 450 digital pathology scanner¹ and Aperio HALO AP.® Enable a seamless AI-powered pathology workflow with our image management solution¹ and Lunit SCOPE biomarker scoring algorithm¹.
“As a first step, we are integrating Lunit’s algorithms directly into our image management software powered by Indica Labs, which enables a continuous workflow for users of the Aperio GT 450 scanner,” said Karan Arora, senior vice president of advanced assays, AI and pharmaceutical partnerships at Leica Biosystems. “This announcement aligns with our long-term vision to deliver scalable, seamlessly integrated research workflows to the market.”
Commitment to open pathology and interoperability
This three-way integration reflects a shared commitment to open pathology and interoperability across the digital pathology ecosystem. Indica Labs CEO Steven Hashagen emphasized that “a robust end-to-end solution like this is an important step in realizing the potential of AI in digital pathology.”
Lunit CEO Brandon Suh added, “We are encouraged by the strong interest from our pharmaceutical partners and excited about the potential of this collaboration. Together, we are applying AI to pathology image analysis at an unprecedented scale with the common goal of delivering highly accurate diagnostics that lead to measurable improvements in patient care.”
References
1. For research use only. Not for use in diagnostic procedures.
2. Aperio HALO AP® Marked with CE-IVDR in vitro It is used diagnostically in Europe, the UK and Switzerland. Aperio HALO AP® For research use only in the United States and is not FDA cleared for clinical diagnostic use.
This news contains forward-looking statements.
